{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-016912","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.239315+00:00","generated_at":"2026-05-16T02:24:01.994422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M","bullets":["Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).","Net loss $1.4M ($0.03/sh) vs net income $1.8M ($0.06/sh) in Q1 FY25 due to no license revenue.","Cash $3.6M as of Dec 31, 2025; funded through FY26 if milestones hit.","Completed 9 trigeminal neuralgia cases after FDA clearance; all patients reportedly pain free.","Expects FY26 product revenue of at least $10.5M, a 17% YoY increase from $9.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-016912","json":"https://secwatch.observer/filing/0001213900-26-016912.json","markdown":"https://secwatch.observer/filing/0001213900-26-016912.md","text":"https://secwatch.observer/filing/0001213900-26-016912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026016912/0001213900-26-016912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026016912/ea0277131-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:24:01.994422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}